or Try an Advanced Search...

    Technical Analysis for VRNA - Verona Pharma plc

    Grade Last Price % Change Price Change
    A 38.73 -0.31% -0.12
    VRNA closed up 2.0 percent on Wednesday, November 20, 2024, on 1.21 times normal volume.
    4 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Up Up Up
    Historical VRNA trend table...
    Date Alert Name Type % Chg
    Crossed Above 20 DMA Bullish 1.68%
    Gapped Up Strength 1.68%
    20 DMA Resistance Bearish 10.85%
    Outside Day Range Expansion 10.85%
    Fell Below 20 DMA Bearish 9.50%
    MACD Bearish Signal Line Cross Bearish 9.50%
    Overbought Stochastic Strength 9.50%
    Down 3 Days in a Row Weakness 9.50%
    Slingshot Bullish Bullish Swing Setup 4.87%
    Upper Bollinger Band Walk Strength 4.87%
    Older End-of-Day Signals for VRNA ...

       Recent Intraday Alerts

    Alert Time
    1.5x Volume Pace about 3 hours ago
    Down 1% about 4 hours ago
    Rose Above Previous Day's High about 4 hours ago
    Up 1% about 4 hours ago
    Up 3% about 22 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    VRNA Chart by TradingView
    Basic chart:

    Profile

    Verona Pharma plc, a clinical stage biopharmaceutical company, researches, discovers, and develops therapeutic drugs to treat respiratory diseases primarily in the United Kingdom and North America. The company's lead product is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which is in Phase IIa clinical trial that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, and asthma. Verona Pharma plc is based in London, the United Kingdom.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Asthma Respiratory Therapy Chronic Obstructive Pulmonary Disease Respiratory Diseases Cystic Fibrosis Phosphodiesterase Lung Disorders

    Is VRNA a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 19 Verona Pharma Announces December 2024 Investor Conference Participation
    Nov 14 Druckenmiller's Duquesne closes some media holdings, loads into regional banks, among Q3 trades
    Nov 5 Verona Pharma (NASDAQ:VRNA) shareholder returns have been incredible, earning 724% in 5 years
    Nov 5 Verona Pharma PLC (VRNA) Q3 2024 Earnings Call Highlights: Strong Ohtuvayre Launch Amid Rising Costs
    Nov 5 Verona Pharma to Present at Jefferies London Healthcare Conference
    Nov 4 Verona Pharma plc (VRNA) Q3 2024 Earnings Call Transcript
    Nov 4 Verona Pharma reports Q3 results
    Nov 4 Verona Pharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update
    Nov 1 Verona Pharma Q3 2024 Earnings Preview
    Oct 25 Recent Price Trend in Verona Pharma (VRNA) is Your Friend, Here's Why
    See more VRNA news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 40.035
    52 Week Low 11.395
    Average Volume 955,336
    200-Day Moving Average 21.88
    50-Day Moving Average 33.30
    20-Day Moving Average 36.39
    10-Day Moving Average 37.55
    Average True Range 1.82
    RSI (14) 62.41
    ADX 32.98
    +DI 29.94
    -DI 17.48
    Chandelier Exit (Long, 3 ATRs) 34.58
    Chandelier Exit (Short, 3 ATRs) 37.06
    Upper Bollinger Bands 40.62
    Lower Bollinger Band 32.15
    Percent B (%b) 0.79
    BandWidth 23.27
    MACD Line 1.23
    MACD Signal Line 1.40
    MACD Histogram -0.1741
    Fundamentals Value
    Market Cap 3.11 Billion
    Num Shares 79.9 Million
    EPS -0.56
    Price-to-Earnings (P/E) Ratio -69.38
    Price-to-Sales 2981.17
    Price-to-Book 5.16
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 41.43
    Resistance 3 (R3) 41.30 40.32 41.00
    Resistance 2 (R2) 40.32 39.66 40.38 40.86
    Resistance 1 (R1) 39.58 39.25 39.95 39.71 40.71
    Pivot Point 38.60 38.60 38.78 38.66 38.60
    Support 1 (S1) 37.86 37.94 38.23 37.99 36.99
    Support 2 (S2) 36.88 37.53 36.94 36.84
    Support 3 (S3) 36.14 36.88 36.70
    Support 4 (S4) 36.27